Table of Contents
Large pharma companies have yet to take on a full-blown adoption of metabolomic technologies, when compared to proteomic and genomic research. This is because of the lingering uncertainties as to the advantages offered by metabolomics that have been the outcome of failed proteomics and genomics research programs. Through some recent accomplishments have been able to dispel some of these doubts, wider adoption and acceptance of metabolomics would necessitate additional landmark successes in R&D. In all probability, the future of metabolomics is slated to hinge on discovering biomarkers for determining the presence of disease in an individual biological system. As biological inputs, such as blood glucose levels for diabetes or high cholesterol levels for heart disease, are already being utilized for confirming disease presence, metabolomics can derive benefit from an understanding of biochemical pathways. The existing focus of metabolomics has been on 20-100 different metabolites and while this constitutes a very small proportion compared to other fields of “omics,” this discipline has been making robust progress in discovering biomarkers.
Metabolomics analytical techniques analyzed in this report includes Separation Techniques – Capillary Electrophoresis, Gas Chromatography, High Performance Liquid Chromatography (HPLC) and Ultra Performance Liquid Chromatography (UPLC); and Detection Techniques – Mass Spectrometry, Nuclear Magnetic Resonance Spectroscopy and Surface-Based Mass Analysis. The report also analyzes the metabolomics applications comprising Biomarker Discovery, Drug Discovery, Nutrigenomics, Toxicology Testing and Other Applications. Metabolomics therapeutic areas explored in this study includes Cardiology, Neurology, Oncology and Other Diseases.
The global markets for the above mentioned metabolomic analytical techniques, end-use applications and the therapeutic areas are analyzed in terms of value in USD. Metabolomic separation techniques account for over half of the global metabolomics market estimated at US$395.2 million in 2014 while detection techniques shares with US$308.8 million. Biomarker discovery projected to be the fastest growing end use sector with 2014-2020 CAGR of 25.2% and also estimated the largest market for metabolomics in 2014 with US$252.8 million closely followed by drug discovery with US$211.1 million.
The report reviews, analyses and projects the metabolomics technologies, applications and therapeutic areas market for global and the regional markets including North America, Europe, Asia-Pacific and Rest of World. The regional markets further analyzed for 9 independent countries across North America – The United States and Canada; Europe – France, Germany, Italy and the United Kingdom; Asia-Pacific – China, India and Japan.
This 508 page global market report includes 306 charts (includes a data table and graphical representation for each chart), supported with meaningful and easy to understand graphical presentation, of market numbers. This report profiles 20 key global players and 33 major players across North America – 20; Europe – 9; and Asia-Pacific – 4. The research also provides the listing of the companies engaged in research and development, manufacturing and supply of metabolomics technologies and instruments. The global list of companies covers addresses, contact numbers and the website addresses of 92 companies.
Get Industry Insights. Simply.
Talk to Veronica
+1 718 514 2762
Use this report to: - Assess current market dynamics and estimate future demand for sample preparation in genomics, proteomics and epigenomics. - Gain insight into existing products as well as new developments ...
Respondents Show Vivid Interest in Developing Clinical NGS-based Tests for Infectious Disease Testing Applications The primary goal of this research is to analyze the current and future adoption plans ...
Global Non-alcoholic Steatohepatitis Biomarker Market: Overview Non-alcoholic steatohepatitis (NASH) is liver disease which is categorized under the spectrum of non-alcoholic fatty liver disease (NAFLD). ...